Prostate-specific membrane antigen-targeted radiohalogenated PET and therapeutic agents for prostate cancer

Journal of Nuclear Medicine

Volumn 57, Issue , 2016, Pages 90S-96S

  Rowe, Steven P ^a   Drzezga, Alexander ^b   Neumaier, Bernd ^b   Dietlein, Markus ^b   Gorin, Michael A ^a   Zalutsky, Michael R ^c   Pomper, Martin G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

18F; 211At; Biochemical recurrence; PET; Prostate specific membrane antigen

Indexed keywords

ASTATINE 211; CARBON 11; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; IODINE 125; IODINE 131; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN INHIBITOR; RADIOHALOGENATED AGENT; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; HALOGEN; PROSTATE SPECIFIC ANTIGEN; RADIOISOTOPE;

ALPHA RADIATION; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG SYNTHESIS; HUMAN; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM CELL; SENSITIVITY AND SPECIFICITY; TUMOR VASCULARIZATION; ANTAGONISTS AND INHIBITORS; DIAGNOSTIC IMAGING; EVIDENCE BASED MEDICINE; GENETIC PROCEDURES; IMAGE ENHANCEMENT; MALE; METABOLISM; POSITRON EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EVIDENCE-BASED MEDICINE; HALOGENS; HUMANS; IMAGE ENHANCEMENT; MALE; MOLECULAR PROBE TECHNIQUES; MOLECULAR TARGETED THERAPY; POSITRON-EMISSION TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 84991409042     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.170175     Document Type: Article

References (67)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65: 87-108.
2. Weinreb JC, Barentsz JO, Choyke PL, et al. PI-RADS Prostate Imaging-Reporting and Data System: 2015, Version 2. Eur Urol. 2016; 69: 16-40.
3. Silverman JM, Krebs TL. MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy. AJR. 1997; 168: 379-385.
4. Hricak H, Schoder H, Pucar D, et al. Advances in imaging in the postoperative patient with a rising prostate-specific antigen level. Semin Oncol. 2003; 30: 616-634.
5. Kane CJ, Amling CL, Johnstone PA, et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 2003; 61: 607-611.
6. Le JD, Tan N, Shkolyar E, et al. Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology. Eur Urol. 2015; 67: 569-576.
7. 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis. 2012; 15: 45-55.
8. 18F]FMAU and positron emission tomography in patients with cancer. Eur J Nucl Med Mol Imaging 2005; 32: 15-22.
9. 18F-fluoro-5a-dihydrotestosterone (FDHT) in prostate tumors as measured by PET. J Nucl Med. 2010; 51: 183-192.
10. 64Culabeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer. J Nucl Med. 2011; 52: 470-477.
11. 18F]bombesin (BAY 86-4367) as imaging probes for prostate cancer in a PC-3 prostate cancer xenograft model. Mol Imaging Biol. 2016; 18: 393-401.
12. Kiess AP, Cho SY, Pomper MG. Translational molecular imaging of prostate cancer. Curr Radiol Rep. 2013; 1: 216-226.
13. Maurer T, Eiber M, Schwaiger M, Gschwend JE. Current use of PSMA-PET in prostate cancer management. Nat Rev Urol. 2016; 13: 226-235.
14. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 1998; 52: 637-640.
15. Perner S, Hofer MD, Kim R, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol. 2007; 38: 696-701.
16. Ross JS, Sheehan CE, Fisher HA, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res. 2003; 9: 6357-6362.
17. Manyak MJ Indium-111 capromab pendetide in the management of recurrent prostate cancer. Expert Rev Anticancer Ther. 2008; 8: 175-181.
18. 89Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy. J Urol. 2014; 191: 1439-1445.
19. 89Zr-J591 immunoPET as a molecular imaging agent for metastatic prostate cancer. Clin Cancer Res. 2015; 21: 5277-5285.
20. Barrett JA, Coleman RE, Goldsmith SJ, et al. First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer. J Nucl Med. 2013; 54: 380-387.
21. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer. J Nucl Med. 2013; 54: 1369-1376.
22. 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med. 2012; 53: 1883-1891.
23. 18F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol. 2015; 17: 565-574.
24. 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015; 42: 197-209.
25. 68gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol. 2016; 195: 1436-1443.
26. 3]-octreotate in the treatment of midgut neuroendocrine tumors. Future Oncol. 2016; 12: 313-321.
27. 177Lu-labeled PSMA I & T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med. 2015; 56: 1169-1176.
28. 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med. 2016; 57: 1006-1013.
29. Zhou J, Neale JH, Pomper MG, Kozikowski AP. NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat Rev Drug Discov. 2005; 4: 1015-1026.
30. 18F]fluorobenzoyllysinepentanedioic acid carbamates: new scaffolds for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA). J Med Chem. 2016; 59: 206-218.
31. Eder M, Eisenhut M, Babich J, Haberkorn U. PSMA as a target for radiolabelled small molecules. Eur J Nucl Med Mol Imaging 2013; 40: 819-823.
32. Machulkin AE, Ivanenkov YA, Aladinskaya AV, et al. Small-molecule PSMA ligands: current state, SAR and perspectives. J Drug Target. 2016; 24: 679-693.
33. Kiess AP, Banerjee SR, Mease RC, et al. Prostate-specific membrane antigen as a target for cancer imaging and therapy. Q J Nucl Med Mol Imaging 2015; 59: 241-268.
34. 11C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALA-Dase). Mol Imaging 2002; 1: 96-101.
35. Foss CA, Mease RC, Fan H, et al. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res. 2005; 11: 4022-4028.
36. Chen Y, Foss CA, Byun Y, et al. Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. J Med Chem. 2008; 51: 7933-7943.
37. 131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging 2014; 41: 1280-1292.
38. 18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res. 2008; 14: 3036-3043.
39. 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015; 56: 668-674.
40. 18F-DCFBC PET/CT for PSMA-based detection and characterization of primary prostate cancer. J Nucl Med. 2015; 56: 1003-1010.
41. 18F-DCFBC PET/CT to conventional imaging modalities for detection of hormone-naïve and castration-resistant metastatic prostate cancer. J Nucl Med. 2016; 57: 46-53.
42. 18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res. 2011; 17: 7645-7653.
43. 18F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging 2014; 41: 89-101.
44. 18F]fluorocholine PET-CT (phase I study). Mol Imaging Biol. 2015; 17: 424-433.
45. Parker C, Gillessen S, Heidenreich A. Horwich A; ESMO Guidelines Committee. Cancer of the prostate: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26(suppl 5): v69-v77.
46. Uchio EM, Aslan M, Wells CK, Calderone J, Concato J. Impact of biochemical recurrence in prostate cancer among US veterans. Arch Intern Med. 2010; 170: 1390-1395.
47. 223Ra-dichloride in patients with hormone-refractory prostate cancer and skeletal metastases. J Nucl Med. 2015; 56: 1304-1309.
48. Maurer T, Weirich G, Schottelius M, et al. Prostate-specific membrane antigenradioguided surgery for metastatic lymph nodes in prostate cancer. Eur Urol. 2015; 68: 530-534.
49. 68Ga] Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol. 2015; 17: 575-584.
50. Sanchez-Crespo A. Comparison of gallium-68 and fluorine-18 imaging characteristics in positron emission tomography. Appl Radiat Isot. 2013; 76: 55-62.
51. Hillier SM, Maresca KP, Femia FJ, et al. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res. 2009; 69: 6932-6940.
52. Aghevlian S, Boyle AJ, Reilly RM. Radioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radionuclides emitting a-particles or Auger electrons. Adv Drug Deliv Rev. December 17, 2015 [Epub ahead of print].
53. Zalutsky MR Radionuclide therapy. In: Vértes A, Nagy S, Klencsár Z, et al., eds. Handbook of Nuclear Chemistry: Radiochemistry and Radiopharmaceutical Chemistry in Life Sciences. 2nd ed. Vol. 4. Berlin, Germany: Springer; 2011: 2179-2212.
54. Parker C, Heinrich D, O'Sullivan JM, et al. Overall survival benefit of radium-223 chloride (Alpharadin™) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomized trial (ALSYMPCA) [abstract]. Eur J Cancer 2011; 47(suppl 2): 3.
55. Kiess AP, MINN I, Chen Y, et al. Auger radiopharmaceutical therapy targeting prostate-specific membrane antigen. J Nucl Med. 2015; 56: 1401-1407.
56. Kassis AI The amazing world of Auger electrons. Int J Radiat Biol. 2004; 80: 789-803.
57. 211At] astatobenzamido)pentyl)ureido)-pentanedioic acid for PSMA-targeted a-particle radiopharmaceutical therapy. J Nucl Med. May 26, 2016 [Epub ahead of print].
58. 211At]-astatinated radio-pharmaceuticals and applications in targeted a-particle therapy. Cancer Biother Radiopharm. 2013; 28: 1-20.
59. Rovenská M, Hlouchova K, Sacha P, et al. Tissue expression and enzymologic characterization of human prostate specific membrane antigen and its rat and pig orthologs. Prostate. 2008; 68: 171-182.
60. 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med. 2015; 56: 1185-1190.
61. Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovas-culature. Clin Cancer Res. 1999; 5: 2674-2681.
62. 68Ga-PSMA PET/CT imaging ofmetastatic clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging 2014; 41: 1461-1462.
63. 18F-DCFPyL PET/CT. Ann Nucl Med. 2015; 29: 877-882.
64. 18F-DCFPyL PET/CT in a patient with metastatic renal cell carcinoma. Clin Nucl Med. 2016; 41: 83-85.
65. 68Ga]PSMA-HBED-CC PET/CT. Eur J Nucl Med Mol Imaging 2015; 42: 1622-1623.
66. 68Ga-PSMA imaging of metastatic breast cancer. Eur J Nucl Med Mol Imaging 2015; 42: 1482-1483.
67. 68Ga-PSMA PET/CT. Clin Nucl Med. 2016; 41: e167-e168.